Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
231.58
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval
July 09, 2021
Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval.
Via
Investor's Business Daily
Exposures
Product Safety
Biogen Slides As FDA Calls For Investigation Into Approval Of Controversial Alzheimer's Drug
July 09, 2021
Shares of Biogen sank to their lowest levels of the session, weighing on the broader biotech sector.
Via
Talk Markets
Exposures
Product Safety
FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval
July 09, 2021
Biogen Inc. (NASDAQ:BIIB) shares came under pressure Frida...
Via
Benzinga
Exposures
Product Safety
Understanding Biogen's Unusual Options Activity
July 09, 2021
On Friday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $369.73. Sentiment: BULLISH Option Type: SWEEP Trade...
Via
Benzinga
Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More
July 09, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is intrigued about Anavex Life Sciences Corp (NASDAQ: AVXL) because Biogen Inc (NASDAQ: BIIB) data doesn...
Via
Benzinga
Friday Trades And June Summary
July 03, 2021
Trading performance has been very good year to date. I had thought I needed to tighten my belt but I made it by just fine.
Via
Talk Markets
What 17 Analyst Ratings Have To Say About Biogen
June 28, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:
Via
Benzinga
Should Biogen Worry About a Congressional Investigation Into Its Alzheimer's Disease Drug?
July 09, 2021
The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.
Via
The Motley Fool
Exposures
Product Safety
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
July 08, 2021
What did the stock market do today? Well, it did a little bit of everything, with short squeezes, crypto gains, IPO hype and regulation fears.
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
Baidu And Nvidia Lead The QQQ Lower Thursday
July 08, 2021
U.S. indices were trading lower Thursday amid concerns the economic recovery is slowing. Growing concerns over the COVID-19 Delta variant have also...
Via
Benzinga
Exposures
COVID-19
Forget a Bear Market -- These 2 Nasdaq Stocks Are Moving Higher
July 08, 2021
Even with markets suffering, there were still some positives on Wall Street.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Biogen Stock Pops Despite New FDA Limits On Alzheimer's Drug Use
July 08, 2021
Biogen stock rose Thursday after the Food and Drug Administration signed off on narrower recommendations for Alzheimer's drug Aduhelm.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
July 08, 2021
Biogen Inc. (NASDAQ:BIIB) shares are lower after the compa...
Via
Benzinga
Exposures
Product Safety
Oracle And CarMax Lead The SPY Higher Wednesday
July 07, 2021
U.S. indices were trading higher Wednesday after the 10-year treasury yield fell to its lowest level since February at 1.3%. The ...
Via
Benzinga
Is Eli Lilly a Better Alzheimer's Stock Than Biogen?
July 07, 2021
An unusually lenient FDA is a knife that cuts both ways for Biogen.
Via
The Motley Fool
Exposures
Product Safety
Unusual Options Activity Insight: Biogen
July 06, 2021
Biogen (NASDAQ:BIIB) shares experienced unusual options activity on Tuesday. The stock price moved down to $343.7 following the option alert. Sentiment: NEUTRAL Option Type:...
Via
Benzinga
Lundbeck Out Licenses Flopped Alzheimer's Drug In Wake Of Biogen's Controversial Success With Aducanumab
July 02, 2021
Privately-held Denovo Biopharma LLC has in-licensed global rights for idalopirdine from H. Lundbeck A/S (OTC: HLUYY) for all indications. The deal...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
July 01, 2021
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...
Via
Benzinga
Analyzing Biogen's Unusual Options Activity
June 30, 2021
On Wednesday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $348.49. Sentiment: BEARISH Option Type: TRADE...
Via
Benzinga
How Biogen Made an Enemy of 1 of the Biggest Supporters of Its Alzheimer's Disease Drug
June 30, 2021
A nonprofit group doesn't like a recent move by Biogen.
Via
The Motley Fool
Exposures
Product Safety
3 Better Alzheimer’s Drug Stocks to Buy Instead of Biogen
June 29, 2021
These drug stocks are in competition with Biogen for an Alzheimer's treatment, and can break out in a similar fashion offering better value.
Via
InvestorPlace
Could Biogen's Big Win With Aduhelm Become a Big Liability?
June 29, 2021
It's looking more and more likely.
Via
The Motley Fool
How Bad Is Biogen's Latest Bad News?
June 29, 2021
The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks.
Via
The Motley Fool
Facebook And Nvidia Lead The QQQ Higher Monday
June 28, 2021
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve...
Via
Benzinga
Earnings Roundup: Adobe, Kroger, The Honest Company, and More
June 28, 2021
Discussing the latest news and how to move from growth-focused investing to a value approach.
Via
The Motley Fool
Biogen's Costly Alzheimer's Treatment May Face Restricted Medicare Access: WSJ
June 28, 2021
The recent approval of Biogen Inc's (NASDAQ: BIIB) high-price Alzheimer's drug is raising questions about who will have access to the $56,000/year...
Via
Benzinga
Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials
June 28, 2021
Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green...
Via
Benzinga
New Alzheimer’s Treatment Is A Huge Catalyst for Biogen
June 28, 2021
BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth.
Via
InvestorPlace
10 Biggest Price Target Changes For Monday
June 28, 2021
Barclays raised the price target for Accenture plc (NYSE:
Via
Benzinga
The Upside for Biogen Is Absolutely Wild
June 26, 2021
It's hard to believe how large Biogen's market opportunity is, now that the FDA has approved its Alzheimer's drug.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Product Safety
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.